About G-protein coupled receptor 68
G-protein coupled receptor 68 (GPR68) is a protein
from Homo sapiens identified by UniProt accession
Q15743, 365 residues long.
MolForge cross-references it against 0 known binders and
226 disease associations.
Target properties
| Protein name | G-protein coupled receptor 68 |
|---|
| UniProt accession | Q15743 |
|---|
| Gene | GPR68 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 365 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (226)
Diseases linked to this target (Open Targets).
- Hypomaturation amelogenesis imperfecta · score 0.62
- amelogenesis imperfecta · score 0.48
- neurodegenerative disease · score 0.37
- glioblastoma multiforme · score 0.27
- breast carcinoma · score 0.17
- ovarian carcinoma · score 0.16
- prostate carcinoma · score 0.16
- age-related hearing impairment · score 0.15
- neoplasm · score 0.11
- urinary metabolite measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15743-F1 | alphafold | PREDICTED | 80.41 | — |
Amino-acid sequence (365 residues)
MGNITADNSS MSCTIDHTIH QTLAPVVYVT VLVVGFPANC LSLYFGYLQI KARNELGVYL CNLTVADLFY ICSLPFWLQY VLQHDNWSHG DLSCQVCGIL LYENIYISVG FLCCISVDRY LAVAHPFRFH QFRTLKAAVG VSVVIWAKEL LTSIYFLMHE EVIEDENQHR VCFEHYPIQA WQRAINYYRF LVGFLFPICL LLASYQGILR AVRRSHGTQK SRKDQIQRLV LSTVVIFLAC FLPYHVLLLV RSVWEASCDF AKGVFNAYHF SLLLTSFNCV ADPVLYCFVS ETTHRDLARL RGACLAFLTC SRTGRAREAY PLGAPEASGK SGAQGEEPEL LTKLHPAFQT PNSPGSGGFP TGRLA
Explore G-protein coupled receptor 68 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets